Trial Search Results

Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients With Stage II-III Non-small Cell Lung Cancer

This phase I trial studies how well giving accelerated hypofractionated or conventionally fractionated radiation therapy and durvalumab works in treating patients with stage II-III non-small cell lung cancer. Accelerated hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Conventionally fractionated radiation therapy delivers smaller doses of radiation therapy over time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving accelerated hypofractionated radiation therapy or conventionally fractionated radiation therapy with durvalumab will work better in treating patients with non-small cell lung cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Collaborator: NRG Oncology

Stanford Investigator(s):

Intervention(s):

  • Biological: Durvalumab
  • Radiation: Fractionated Stereotactic Radiation Therapy
  • Radiation: Hypofractionated Radiation Therapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Pathologic (cytological or histological) proof of diagnosis of stage II-III (American
   Joint Committee on Cancer [AJCC] 8th edition [ed.]) unresectable or inoperable,
   non-metastatic non-small cell lung cancer (NSCLC) within 60 days prior to
   registration, with no liver or renal end organ damage, as determined by normal
   laboratory values noted below. Locally recurrent, N1-N3 disease following surgery
   without prior radiation therapy is eligible. Patients with N1 to N3 and undetectable
   primary lung tumors (T0) are eligible

   - Pathological diagnosis of PD-L1 high expressing tumors (>= 50%) within 60 days prior
   to registration (using Dako 22C3 immunohistochemistry [IHC] antibody platform)
   performed at a Clinical Laboratory Improvement Act (CLIA)-certified lab

   - Appropriate stage for study entry based on the following diagnostic workup:

      - History/physical examination within 30 days prior to registration;

      - Positron emission tomography (PET)/computed tomography (CT) scan for staging
      within 30 days prior to registration (note: if CT portion of PET/CT scan is not
      of diagnostic quality, then a separate CT scan with contrast is required);

      - Magnetic resonance imaging (MRI) scan of the brain with contrast; if medically
      contraindicated, then CT scan of the brain with contrast (unless medically
      contraindicated) is acceptable, within 30 days prior to registration;

      - Sufficient lung function with forced expiratory volume in 1 second (FEV1) >= 0.8
      liter or >= 35% predicted and carbon monoxide diffusing capability (DLCO) >= 40%
      with or without bronchodilator within 30 days prior to registration;

      - Patients who meet the criterion above without oxygen (O2), but who need acute
      (started within 10 days prior to registration) supplemental oxygen due to
      tumor-caused obstruction/hypoxia are eligible, provided the amount of the O2
      needed has been stable

   - Body weight > 30 kg

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 30 days
   prior to registration

   - Absolute neutrophil count (ANC) >= 1500 cells/mm^3 (within 30 days prior to
   registration)

   - Lymphocyte count >= 500 cells/mm^3 (within 30 days prior to registration)

   - Platelet count >= 100,000 cells/mm^3 (within 30 days prior to registration)

   - Hemoglobin >= 9.0 g/dL (within 30 days prior to registration) (Note: The use of
   transfusion or other intervention to achieve hemoglobin [Hgb] >= 9.0 g/dl is
   acceptable)

   - Glomerular filtration rate (GFR) >= 40 mL/min/1.73 m^2 (within 30 days prior to
   registration)

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) with the following exception
   (within 30 days prior to registration):

      - Patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may
      be enrolled

   - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
   (within 30 days prior to registration)

   - Evidence of post-menopausal status or negative urinary or serum pregnancy test for
   female pre-menopausal patients, obtained within 14 days prior to registration. Women
   will be considered post-menopausal if they have been amenorrheic for 12 months without
   an alternative medical cause. The following age-specific requirements apply:

      - Women < 50 years of age would be considered post-menopausal if they have been
      amenorrheic for 12 months or more following cessation of exogenous hormonal
      treatments and if they have luteinizing hormone and follicle-stimulating hormone
      levels in the post-menopausal range for the institution or underwent surgical
      sterilization (bilateral oophorectomy or hysterectomy)

      - Women >= 50 years of age would be considered post-menopausal if they have been
      amenorrheic for 12 months or more following cessation of all exogenous hormonal
      treatments, had radiation-induced menopause with last menses > 1 year ago, had
      chemotherapy-induced menopause with last menses > 1 year ago, or underwent
      surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or
      hysterectomy)

   - Patients who are human immunodeficiency virus (HIV) positive may participate IF they
   meet the following eligibility requirements:

      - They must be stable on their anti-retroviral regimen, and they must be healthy
      from an HIV perspective

      - They must have a CD4 count of greater than 250 cells/mcL

      - They must not be receiving prophylactic therapy for an opportunistic infection

   - The patient or a legally authorized representative must provide study-specific
   informed consent prior to study entry

Exclusion Criteria:

   - Definitive clinical or radiologic evidence of metastatic disease

   - Prior invasive malignancy (except those with a negligible risk of metastasis or death
   and with expected curative outcome [such as adequately treated carcinoma in situ of
   the cervix, basal or squamous cell skin cancer, localized prostate cancer treated
   surgically with curative intent, or ductal carcinoma in situ treated surgically with
   curative intent] or undergoing active surveillance per standard-of-care management
   [e.g., chronic lymphocytic leukemia (CLL) Rai stage 0, prostate cancer with Gleason
   score =< 6, and prostate specific antigen (PSA) =< 10 mg/mL]) unless disease free for
   a minimum of 3 years

   - Prior chemotherapy or systemic therapy for the study cancer; note that prior
   chemotherapy for a different cancer is allowable

   - Prior radiotherapy to the region of the study cancer that would result in overlap of
   radiation therapy fields so that cumulative composite dose combining previous plan and
   current plan to be within 80 Gy to the trachea, major blood vessels, esophagus, and
   heart, and 55 Gy to the spinal cord (if such patients are being considered, this will
   need to be centrally reviewed). Prior chest radiation without overlap is permissible

   - History of autoimmune disease, including but not limited to systemic lupus
   erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis
   associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's
   syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or
   glomerulonephritis. Patients with a history of treated autoimmune thyroid disease
   requiring thyroid replacement but not immunosuppressives, as well as type 1 diabetes,
   are permitted. Patients with vitiligo, psoriasis not requiring systemic treatment, or
   conditions not expected to recur in the absence of an external trigger are permitted
   to enroll

   - History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),
   organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing
   pneumonia, etc.), or evidence of active pneumonitis on chest PET/CT or CT scan

   - Severe, active co-morbidity defined as follows:

      - Known clinically significant liver disease, including active viral, alcoholic, or
      other hepatitis, cirrhosis, fatty liver, and inherited liver disease;

      - Any other diseases, metabolic dysfunction, physical examination finding, or
      clinical laboratory finding giving reasonable suspicion of a disease or condition
      that contraindicates the use of an investigational drug or that may affect the
      interpretation of the results or render the patient at high risk from treatment
      complications;

      - Active tuberculosis (clinical evaluation that includes clinical history, physical
      examination and radiographic findings, and tuberculosis [TB] testing in line with
      local practice);

      - Active hepatitis B (chronic or acute) or hepatitis C infection. Patients with
      past or resolved hepatitis B infection defined as having a negative hepatitis B
      surface antigen (HBsAg) test, a positive anti-HBc [antibody to hepatitis B core
      antigen], and a negative viral deoxyribonucleic acid (DNA) test (only obtained if
      HBsAg is found positive) are eligible. Patients positive for hepatitis C virus
      (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative
      for HCV ribonucleic acid (RNA)

   - Pregnancy or women of childbearing potential and men who are sexually active and not
   willing/able to use medically acceptable forms of contraception during treatment and
   for 3 months after the last dose of MEDI4736 (durvalumab); this exclusion is necessary
   because the treatment involved in this study may be significantly teratogenic. Women
   who are breastfeeding are also excluded

   - Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria
   for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the
   exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
   criteria:

      - Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis
      after consultation with the study physician.

      - Patients with irreversible toxicity not reasonably expected to be exacerbated by
      treatment with durvalumab may be included only after consultation with the study
      physician

   - Major surgical procedure (as defined by the investigator) within 28 days prior to the
   first dose of investigational product (IP). Note: Local surgery of isolated lesions
   for palliative intent is acceptable

   - History of allogenic organ transplantation

   - History of leptomeningeal carcinomatosis

   - History of active primary immunodeficiency

   - Current or prior use of immunosuppressive medication within 14 days before the first
   dose of durvalumab. The following are exceptions to this criterion:

      - Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
      articular injection);

      - Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of
      prednisone or its equivalent;

      - Steroids as premedication for hypersensitivity reactions (e.g., CT scan
      premedication)

   - Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note:
   Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to
   30 days after the last dose of IP

   - Known allergy or hypersensitivity to any of the study drugs or any of the study drug
   excipients

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kim Nguyen
(650) 497-8966
Not Recruiting